Principal Responsibility; General Statement. The parties’ intention is the smooth and efficient conduct of development, and the parties desire by this Section 2.5 to provide guiding principles by which day-to-day decisions may be made by the responsible party and by which the approval process more particularly described in Section 3 below shall be governed. The parties intend that the Ultrio 2 Assay Product development will be conducted primarily and principally by Gen-Probe. Section 2.5.3 below specifies the development activities that will be the primary responsibility of Novartis. The party to whom principal responsibility is allocated in this Section 2.5 has the power to make day-to-day decisions regarding matters within the area of such responsibility, consistent with the overall Ultrio 2 Development Program. The parties’ obligations with respect to certain warehousing and shipping are subject to Amendment No. 3.
Appears in 1 contract
Sources: Future Blood Screening Assay Ultrio 2 Addendum (Gen Probe Inc)
Principal Responsibility; General Statement. The parties’ ' intention is the smooth and efficient conduct of development, and the parties desire by this Section 2.5 to provide guiding principles by which day-to-day decisions may be made by the responsible party and by which the approval process more particularly described in Section 3 below shall be governed. The parties intend that portions of the Ultrio 2 Assay Product development will be conducted primarily and principally by Gen-Probe. Section 2.5.3 below specifies one or the development activities that will be other of the primary responsibility parties, after consultation and discussion with the other party, under the supervision of Novartisthe Project Manager, as follows: [***]. The party to whom principal responsibility is allocated in this Section 2.5 has the power to make day-to-day decisions regarding matters within the area of such responsibility, consistent with the overall Ultrio 2 Development Program. The parties’ ' obligations with respect to certain warehousing and shipping are subject to Amendment No. 3.
Appears in 1 contract
Sources: Future Blood Screening Assay—ultrio Addendum (Chiron Corp)